Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab
复制标题
DOI：
10.1136/gutjnl-2021-324388
复制
发表时间：
2021-05-01
期刊：
影响因子：
24.5
通讯作者：
Ahmad, Tariq
中科院分区：
文献类型：
--
作者：
Kennedy, Nicholas A.;Goodhand, James R.;Ahmad, Tariq
目的抗肿瘤坏死因子（anti-TNF）药物损害肺炎球菌、流感和病毒性肝炎疫苗接种后的保护性免疫，增加严重呼吸道感染的风险。我们试图确定英夫利昔单抗治疗的IBD患者是否对SARS-CoV-2 infections.Design血清学反应减弱，将英夫利昔单抗治疗的参与者的抗体反应与Vedolizumab治疗的参考队列进行比较，Vedolizumab是一种肠道选择性抗整合素α 4 β 7单克隆抗体，与受损的疫苗反应或对全身感染的易感性增加无关。2020年9月22日至12月23日期间，从英国92家医院招募了6935名患者。英夫利昔单抗治疗患者的血清阳性率低于Vedolizumab治疗患者（3.4%（161/4685）vs 6.0%（134/2250），p
Objective Antitumour necrosis factor (anti-TNF) drugs impair protective immunity following pneumococcal, influenza and viral hepatitis vaccination and increase the risk of serious respiratory infections. We sought to determine whether infliximab-treated patients with IBD have attenuated serological responses to SARS-CoV-2 infections.Design Antibody responses in participants treated with infliximab were compared with a reference cohort treated with vedolizumab, a gut-selective anti-integrin alpha 4 beta 7 monoclonal antibody that is not associated with impaired vaccine responses or increased susceptibility to systemic infections. 6935 patients were recruited from 92 UK hospitals between 22 September and 23 December 2020.Results Rates of symptomatic and proven SARS-CoV-2 infection were similar between groups. Seroprevalence was lower in infliximab-treated than vedolizumab-treated patients (3.4% (161/4685) vs 6.0% (134/2250), p